Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically detailing changes in share interests arising from dividend reinvestment.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details. The only financial figure disclosed is the share price of £10.15 per Ordinary share at the time of the transaction on May 5, 2009.
Material Changes
Material changes reported relate to the shareholdings of specific individuals due to the reinvestment of dividends into Ordinary shares held within an Individual Savings Account (ISA). The changes are as follows:
- Mr A P Witty: 8 shares
- Mr J S Heslop: 10 shares
- Mr S M Bicknell: 49 shares
- Mr E J Gray: 8 shares
- Mr D S Redfern: 8 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification compliant with Disclosure and Transparency Rule 3.1.4R(1)(a) and contains no strategic or operational commentary.
Investor Verification Points
- Verify the total number of shares held by the named directors following the May 5, 2009 transaction.
- Confirm the share price of £10.15 against market data for May 5, 2009.
- Review the company's Form 20-F for comprehensive financial performance data, as this 6-K contains no financial statements.